Company Overview
Mobile-health Network Solutions operates as an investment holding company focused on delivering telehealth solutions primarily within the Singapore market. The organization functions within the healthcare sector, specifically the health information services industry, where it leverages technology to bridge gaps in patient access and medical data management. This entity maintains a workforce of 73 employees to support its dual operational segments: Telemedicine and Other Services, alongside the Sale of Medicine and Medical Devices. The company provides the MaNaDr platform, which serves as a 360-degree healthcare ecosystem designed to integrate various aspects of patient care and service delivery. With a market capitalization of $3.19M and annual revenue of $7.32M, the company represents a small-cap enterprise with a relatively modest scale. These valuation and revenue figures indicate that the business is positioned as a niche player rather than a market leader, suggesting it likely competes on specialized service offerings or regional focus rather than broad market share. The low employee count relative to the revenue base suggests a highly leveraged operational model or significant reliance on external partnerships to deliver services.
Financial Health
The company reported trailing twelve-month revenue of $7.32M, while simultaneously posting a net income of $-2,586,343 and an EBITDA of $-2,503,371. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, exceed gross profits by a wide margin, resulting in a loss on every dollar of revenue generated. Free cash flow is listed as N/A, which indicates that the company is currently consuming cash rather than generating surplus liquidity, thereby limiting its financial flexibility for debt repayment or capital expenditures without external financing. The gross margin stands at 19.7%, indicating that the company retains roughly 20 cents for every dollar of revenue after direct costs, while the operating margin of -22.2% and profit margin of -35.3% highlight severe inefficiencies in overhead management and overall profitability. On the balance sheet, the company holds $3.48M in cash against $115,463 in debt, creating a scenario where liquid assets significantly outweigh liabilities despite the negative earnings. The debt-to-equity ratio of 1.39 suggests a leveraged position, yet the high current ratio of 4.22 indicates robust short-term liquidity, as current assets are more than four times the value of current liabilities. Return on Equity is -47.6% and Return on Assets is -23.5%, metrics that reveal management is currently destroying shareholder value and failing to generate sufficient returns on the capital employed in the business operations.
Valuation Assessment
Trailing P/E and forward P/E ratios are both N/A, reflecting the company's status as a net loss generator where traditional earnings-based valuation multiples are mathematically impossible to calculate without hypothetical assumptions about future profitability. The price-to-book ratio is 0.37, indicating that the market values the company at less than 40% of its book value, which typically suggests investors perceive significant risks or potential issues with the asset quality that depress the stock price below its accounting net worth. The price-to-sales ratio of 0.44 and an EV/EBITDA of 0.13 provide alternative valuation perspectives that show the market is willing to pay less than half of the company's annual sales to own the equity, signaling extreme skepticism regarding future cash flow generation. The stock has traded between a 52-week high of $11.68 and a 52-week low of $0.79, placing the current trading price in a range that requires calculation against the specific market price to determine exact percentage distance from these bounds. The beta value is N/A, meaning that the historical volatility data required to calculate this metric is unavailable or insufficient, making it impossible to quantify the stock's sensitivity to broader market movements relative to the benchmark index.
Growth & Income
Revenue growth year-over-year stands at -7.7%, while earnings growth is N/A due to the persistent net losses reported in the trailing twelve months. The negative revenue growth indicates a contraction in the business's top line, and since earnings are already negative, the concept of earnings growing faster or slower than revenue is moot in the traditional sense as both metrics are trending downward or undefined. As the company does not pay dividends, the dividend yield and payout ratio are both N/A, confirming that the entity retains its meager earnings or cash reserves rather than distributing them to shareholders. The overall growth and income profile is characterized by a shrinking revenue base and an absence of dividend income, leaving investors reliant on potential capital appreciation or a turnaround in profitability to realize any value from the investment.